CA-AGENDIA
Agendia, Inc ., a commercial stage company focused on precision oncology for breast cancer, today announced that it is offering early access to its Digital MammaPrint platform for patients with breast cancer in Brazil, expanding the company’s offerings in the country with the goal of bringing essential information from cancer testing to the larger global breast cancer community. Brazil is the first country to have samples analyzed by Digital MammaPrint, allowing physicians and their patients to benefit from genomic insights derived from a digitized image of a breast cancer tumor. Results about individual tumors will now be informed by the new artificial intelligence (AI) platform, also providing better turnaround time for their treatment decisions.
By offering Brazilian physicians and their patients early access to Digital MammaPrint test results, Agendia expects to be able to reach a patient population that includes the over 66,000 women in Brazil newly diagnosed with breast cancer in 2020 alone, enabling the possibility for earlier and faster intervention for these women along the entire continuum of care.1
“Incorporating AI into the MammaPrint equation for patients with early-stage breast cancer has the potential to be an unprecedented accelerator for the use of genomic testing and diagnostics in the treatment of this disease, and is potentially transformational for women with breast cancer around the world,” said Mark Straley, Chief Executive Officer of Agendia. “Stratifying breast cancer through AI analysis of a tumor tissue image trained by an astounding amount of our proprietary clinical data has the potential to fundamentally change how breast cancer is treated globally. Enabled by Agendia’s deep understanding and expertise in the functional genomics of breast cancer, we are proud to bring the robust science and clinical benefit that MammaPrint provides together with new digital capabilities, informed by the incredible power of AI, to Brazilian physicians and the women they seek to treat.”
Agendia’s Digital MammaPrint is powered by the cloud-based Paige Platform , a partnership that the two companies announced in November 2020 . This is the first product of the collaboration, initially focused on the development of digital tests for early treatment planning where genomic testing has played a crucial role in determining recurrence risk and tumor biology as doctors and their patients make decisions about the path ahead.
“Introducing Digital MammaPrint to physicians and their patients in Brazil marks an important step in increasing access to quality, AI-enabled diagnostic tests,” said David Klimstra, M.D., Founder and Chief Medical Officer at Paige. “We are excited to partner with Agendia to advance our shared goal of transforming pathology data into clear and actionable clinical insights for better patient outcomes.”
On a global scale, access to insights from Digital MammaPrint opens diagnostic care options for women diagnosed with breast cancer worldwide who don’t have access to genomic testing or esoteric lab infrastructure.
“For patients with breast cancer throughout the world who do not live in a location with direct access to genomic testing of their cancer, the ability to obtain such information from a slide image could be revolutionary. The introduction of a digital, AI-informed platform to allow interpretation of the genomic profile of their specific tumor can provide great clinical value and carries the added benefit of preserving valuable tumor tissue for further use in the future. We are using an innovative platform and doing revolutionary work with it,” said William Audeh, M.D., Chief Medical Officer at Agendia. “The ultimate goal is for patients to have access to vital information about their cancer, and this tool has the ability to provide them with that information faster, through digital technology. We believe that the sooner we can get MammaPrint insights into physicians’ hands in their decision-making process, the better it is for their patients.”
Agendia’s MammaPrint is a 70-gene prognostic test that stratifies a specific patient’s recurrence risk and provides a prognostic marker to help inform that risk along with other clinicopathologic factors. MammaPrint informs decisions about pre-operative systemic therapy, adjuvant chemotherapy, and adjuvant endocrine therapy, and the digital capabilities of the test are expected to give physicians and their patients clear and actionable information at these and other critical decision points throughout the cancer care continuum.
About Agendia
Agendia is a mission-driven, commercial stage company focused on enabling optimized decision-making by providing physicians with next-generation diagnostic and information solutions that can be used to help improve outcomes for breast cancer patients worldwide. The company currently offers two commercially-available genomic profiling tests that help surgeons, oncologists and pathologists to personalize treatment for women at critical intervention points throughout their patient journey.
MammaPrint® is a 70-gene prognostic test that, along with other clinicopathologic factors, determines a specific patient’s breast cancer recurrence risk. BluePrint® is an 80-gene molecular subtyping test that identifies the underlying biology of an individual breast cancer to provide information about its behavior, long-term prognosis and potential response to systemic therapy. Together, MammaPrint® and BluePrint® provide a holistic view of an individual patient’s breast cancer, enabling physicians to objectively select the best treatment plan.
For more information on Agendia’s assays and ongoing trials, please visit www.agendia.com .
1 Silva, J et.al. 25 Jan. 2021. Breast Cancer Mortality in Young Women in Brazil. Front. Oncol. 10:569933. Doi: 10.3389/fonc.2020.569933.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220112005659/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Suzano Starts Up New Production Line, Boosting Its Fluff Pulp Capacity by 400%17.12.2025 21:50:00 CET | Press release
A R$490 million investment expands the supply of raw material used in the production of absorbent items Suzano, the world’s largest pulp producer, has commenced operations this week at its new fluff pulp production line located in its Limeira unit in Brazil’s São Paulo state. This R$490 million investment increases Suzano’s total fluff pulp production capacity by more than 400%, from 100,000 to 440,000 tonnes per year. The project involved converting the existing pulp line at the Limeira unit into a flexible machine, capable of producing both Eucafluff® and market pulp. Eucafluff® is used in the production of absorbent and personal hygiene products, such as baby and adult diapers, sanitary pads and pet pads. Then market pulp is supplied for making products including toilet paper, printing and writing papers, and paper packaging. Launched in 2015, Eucafluff® is the world’s first fluff pulp made from eucalyptus, delivering unique advantages like enhanced softness and flexibility, which t
SES Acknowledges Moody’s Rating Action and Reiterates Deleveraging Commitments17.12.2025 21:36:00 CET | Press release
SES S.A. (“SES” or the “Company”), a leading space solutions company, acknowledges the credit rating action announced by Moody’s Investor Service today, which follows the release of SES’ Q3 2025 results and Intelsat integration update. SES management reiterates that the Company continues to execute on its strategy with a clear plan to strengthen its key credit metrics over time. Consistent with this plan, it remains management’s intention to de-lever and return to credit metrics that are commensurate with investment grade, with a policy objective of reducing adjusted net leverage1 to at least 3.0x or below. Today’s rating action does not change the Company’s ability to operate its business, serve customers, or execute its strategic plan. SES maintains a balanced weighted average debt maturity profile of approximately five years, and the rating action from Moody’s is not expected to have a material impact on the interest payable under the Company’s existing debt facilities. SES also ben
Picsart and Zazzle Power the Creator-to-Commerce Evolution with Print-On-Demand Integration17.12.2025 20:47:00 CET | Press release
Partnership Gives Creators an End-to-End Solution to Create A Range of Products in the $205 Billion Creator Economy Picsart, the world’s leading digital creation platform with over two billion downloads and more than 100 million monthly active users, is partnering with Zazzle, the global leader in customized products and designs, to deliver an end-to-end printing solution for Picsart users. The new “vibe-design-to-print” integration works seamlessly with Picsart’s recently expanded suite of AI products, including AI Assistant and Flows, enabling creators to ideate, iterate, design, and bring their work to life as physical art and products. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251217882832/en/ Picsart and Zazzle Power the Creator-to-Commerce Evolution with Print-On-Demand Integration “At Picsart, our mission has always been to give creators the tools they need to bring their ideas to life,” said Hovhannes Avoyan, Fo
Inspiring Leadership Recognised: Anna Byrne Named Finalist at CIPD 2026 HR Awards17.12.2025 19:58:00 CET | Press release
ProAmpac, a global leader in flexible packaging and material science, is proud to announce that Anna Byrne has been selected as a finalist in the “Most Inspirational and Impactful Leader” category at the CIPD 2026 HR Awards in Ireland. This recognition highlights Anna’s exceptional leadership, her unwavering commitment to people-first practices, and her meaningful influence across the organisation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251217690526/en/ The CIPD HR Awards in Ireland The CIPD HR Awards highlight the people profession’s crucial role in driving strategy, leading transformation, and enabling organisations to thrive. Overseen by CIPD Ireland and supported by independent academic expertise, the awards celebrate innovation, integrity, and impact within modern HR practice. This year, the awards introduce four new categories, including the “Most Inspirational and Impactful Leader” award, reflecting the evolvi
GeologicAI Announces Acquisition of Lumo Analytics to Complete Its Integrated Sensor Suite Across Critical Minerals and Rare Earth Elements17.12.2025 17:53:00 CET | Press release
GeologicAI, the global leader in High-Resolution Decision Engineering for the critical minerals sector, today announced its acquisition of Lumo Analytics, a provider of the most compact and efficient Laser-Induced Breakdown Spectroscopy (LIBS) scanner in the market. LIBS is a rapid, non-destructive technique that uses a high-energy laser pulse to vaporize a tiny spot on a rock, creating a short-lived plasma which emits light unique to the elements present when it cools. This spectral “fingerprint” provides immediate chemical information about the material. For the mining sector, this means faster geochemical insights directly at the source, enabling more efficient exploration and resource evaluation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251217715846/en/ The transaction firmly cements GeologicAI’s position as the only truly comprehensive and integrated source of sensor data for the critical minerals industry. Buildi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom